Crown Bioscience
Crown Bioscience, a leading global provider of preclinical and translational research services, is headquartered in the United States. Founded in 2006, the company has established itself as a key player in the biotechnology and pharmaceutical industries, specialising in oncology, immunology, and metabolic diseases. With operational facilities across North America, Europe, and Asia, Crown Bioscience offers a comprehensive suite of services, including in vivo models, biomarker analysis, and drug efficacy testing. What sets Crown Bioscience apart is its commitment to innovation and quality, providing clients with tailored solutions that accelerate drug development. The company has achieved significant milestones, including partnerships with major pharmaceutical firms and contributions to numerous successful clinical trials. As a trusted partner in the life sciences sector, Crown Bioscience continues to enhance its market position through cutting-edge research and a robust portfolio of unique services.
DitchCarbon Score
How does Crown Bioscience's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Crown Bioscience's score of 24 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Crown Bioscience's reported carbon emissions
Crown Bioscience, headquartered in the US, currently does not have publicly available carbon emissions data for recent years. As such, specific figures regarding their emissions in kg CO2e, including Scope 1, 2, or 3 emissions, are not provided. In the absence of detailed emissions data, it is important to note that Crown Bioscience has not outlined any specific reduction targets or commitments to the Science Based Targets initiative (SBTi) or similar climate pledges. This lack of publicly disclosed initiatives may suggest that the company is still in the early stages of formalising its climate commitments or may be focusing on internal strategies that have yet to be communicated. As the industry increasingly prioritises sustainability and carbon reduction, Crown Bioscience's future climate commitments will be crucial in aligning with global efforts to mitigate climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Crown Bioscience is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
